Related Experiment Video

Updated: May 1, 2026

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.6K

Update on romosozumab : a humanized monoclonal antibody to sclerostin

Aline G Costa1, John P Bilezikian, E Michael Lewiecki

  • 1Columbia University, College of Physicians and Surgeons, Division of Endocrinology, Department of Medicine, Metabolic Bone Diseases Unit , 630 West 168th Street, NY 10032 , USA.

Expert Opinion on Biological Therapy
|March 27, 2014
PubMed
Abstract

Insights

Blocking sclerostin with romosozumab shows promise for treating osteoporosis by increasing bone formation. Further studies are needed to confirm its efficacy and safety in large patient groups.

Area of Science:

  • Bone biology
  • Endocrinology
  • Pharmacology

Background:

  • Sclerostin (SOST) negatively regulates bone formation by inhibiting the Wnt signaling pathway.
  • Inactivating SOST gene mutations lead to high bone mass, indicating sclerostin's role in bone metabolism.
  • Understanding sclerostin's mechanism has enabled the development of therapeutic agents.

Purpose of the Study:

  • To evaluate the potential of sclerostin inhibition as an osteoanabolic therapy for osteoporosis.
  • To assess the clinical efficacy and safety of romosozumab, a sclerostin inhibitor.

Main Methods:

  • Romosozumab, a humanized monoclonal antibody targeting sclerostin, was investigated in clinical trials.
  • Preclinical studies with sclerostin antibodies informed the clinical development of romosozumab.

Main Results:

  • Romosozumab demonstrated an increase in bone formation in initial clinical studies.
  • Bone mineral density was shown to increase with romosozumab treatment.
  • Preclinical data supported the anabolic effects observed in human trials.

Conclusions:

  • Pharmacological inhibition of sclerostin with romosozumab represents a novel therapeutic strategy for osteoporosis.
  • Romosozumab holds potential as an osteoanabolic treatment for osteoporosis.
  • Large-scale controlled studies are anticipated to provide comprehensive efficacy and safety data.

More Related Videos

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

26.8K
Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

1.2K

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
615
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755